Skip to content

Merck & Co., Inc.

Merck

MRK · NYSE

Healthcare

Catalog as of September 15, 2026. Not a live market feed.

Fiscal Year
2025
Revenue
$65B
Assets
$136.9B
SEC filing
DEF 14A
Filed
April 8, 2026

Executive Compensation

Compensation reported for Merck’s named executive officers, including salary, stock awards, incentive compensation, other compensation, and total compensation.

Robert M. Davis

Chairman, Chief Executive Officer And President

$20.8M

Reported total · FY2025 · SCT Total as filed

Source: DEF 14A Summary Compensation Table, filed April 8, 2026.

Salary
$1.6M
Stock Awards
$12.1M
Option Awards
$3.4M
Incentives
$2.3M
Other
$1.3M

Historical Compensation

Robert M. Davis total compensation, fiscal years 2023–2025.

Year-by-year total compensation
Fiscal YearSalaryTotal Compensation
2025$1,645,302$20,797,845
2024$1,623,874$23,186,064
2023$1,603,091$20,273,287

Named Executive Officers

Source information

Company
Merck & Co., Inc.
Ticker
MRK · NYSE
Filing type
DEF 14A
Fiscal year
2025
Filing date
April 8, 2026
SEC accession number
0001193125-26-147704

Source: U.S. Securities and Exchange Commission, DEF 14A Summary Compensation Table. View SEC filing

Related Companies